More than 90 million doses of the AstraZeneca COVID-19 vaccine will be produced in Japan by a Japanese pharmaceutical company through a licensing agreement.
It will cover three quarters of the supply the British-Swedish pharmaceutical company has pledged to provide to the country, officials said Thursday.
Many believe vaccination would be key for Japan to hold the postponed Olympics this summer, but prospects are still uncertain in a country known for cautious decision-making process and a public wary of vaccines.
The plan is part of 120 million doses that AstraZeneca promised to supply to Japan under a deal the two sides already agreed upon, says Chief Cabinet Secretary Katsunobu Kato, adding: It is very important to establish vaccine production system in the country.
AstraZeneca has signed a licensing agreement with JCR Pharmaceuticals, based in the Hyogo prefecture in western Japan, the companies say.
The announcement comes as officials are preparing for inoculation in late February, when Japan's health ministry is expected to approve the Pfizer vaccine. Japan is also getting a vaccine supply from Moderna. Japan says it has secured vaccines from the three suppliers for more than the population of 127 million.
Of the 120 million doses AstraZeneca will provide, the remaining 30 million are expected to be imported by March, officials say.
Japan, which is under a partial state of emergency until February 7, has reported 375,607 confirmed cases and 5,361 confirmed deaths.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU